E. Michael Gibbs, Ph.D.                                                                                                                Director of Research                                                                                                                                                      Dr. Gibbs leverages his 20 plus years in the Department of Cardiovascular, Endocrine and Metabolic Diseases at Pfizer to design and execute client proposals. In addition to whole animal physiology, his expertise includes extensive knowledge of the biochemical pathways of insulin signal transduction, glucose transport regulation, and the interactions amongst carbohydrate and lipid metabolic pathways. He is an expert in using in vivo models to test hypotheses on novel drug targets, and then confirming the predicted therapeutic actions in various metabolic disease animal models of multiple experimental (pre-clinical through Phase III) and marketed drugs.

Phillip D. Pratt, Jr., Ph.D.                                                                                                                Associate Professor; Department of Anesthesiology, Pharmacology and Toxicology; Medical College of Wisconsin               Dr. Pratt has over 20 years of experience evaluating the effects of pharmacology agents on the cardiovascular performance, vascular biology, and myocardial reperfusion injury in large and small animal models.

Richard J. Roman, Ph.D.                                                                                                                   Professor and Chairman; Department of Pharmacology and Toxicology; University of Mississippi Medical Center                                     Dr. Roman is a leading expert in cardiovascular physiology, renal physiology and pharmacology. His expertise ranges from whole animal physiology and clinical assay development to molecular biology. Dr. Roman has mastered an array of technologies including micropuncture, tubular perfusion, intracellular imaging, laser Doppler flowmetry, and mass spectroscopy.  

Daniel Sem, Ph.D.                                                                                                                    Director; Center for Structure-based Drug Design & Development; Concordia University Wisconsin                                                              Dr. Sem has 20 years experience studying protein-ligand interactions using various techniques including NMR, fluorescence spectroscopy, steady state kinetics, chemical biology, and computational methods. Dr. Sem also has over 14 years experience in structure-based drug design, both from the scientific perspective, as well as in pharmaceutical development.

Behnam Ghasemzadeh, Ph.D.                                                                                                    Assistant Professor; Department of Biomedical Sciences; Marquette University                                                                                                  Dr. Ghasemzadeh focuses on elucidating the cellular and molecular mechanisms underlying synaptic transmission and synaptic plasticity with an emphasis on the cellular and molecular underpinnings of schizophrenia and drug abuse in the brain and the cellular and molecular plasticity underlying schizophrenia. The goal of his research is to identify molecular changes in the brain that characterize these behavioral states.

Andreas Beyer, Ph.D.                                                                                                                    Instructor; Department of Cardiology; Medical College of Wisconsin                                                                                                                      Dr. Beyer has extensive experience in the evaluation of blood pressure mouse models and vascular function in vivo and in vitro. Dr. Beyer also has experience in the molecular and genetic evaluation of animal models, as well as the generation and management of transgenic animals.

Donald Carrigan, Ph.D.                                                                                                              Founder and Chief Scientist; Wisconsin Viral Research Group                                                                                                                               Dr. Carrigan manages a biomedical research and viral diagnostic laboratory that is GLP and CLIA certified. Dr. Carrigan continues to focus on research involving immuno-compromised patients. 

Konstance K. Knox, Ph.D.                                                                                                          Founder and Chief Scientist; Wisconsin Viral Research Group                                                                                                                                 Dr. Knox manages a biomedical research and viral diagnostic laboratory that is GLP and CLIA certified. Her research interests focus on the role of persistent viral and prion infections in chronic diseases of animals and humans.